REGENXBIO faces lawsuit for misleading investors about RGX-111 gene therapy safety, after FDA halted trials due to a participant’s brain tumor.

The FDA approved BYSANTI, a new antipsychotic for bipolar mania and schizophrenia, with a U.S. launch expected in Q3 2026.

Medicare will now cover FDA-approved multicancer blood/saliva tests, boosting approval efforts despite cost and accuracy challenges.

GVRP and Yurogen partner to boost biologics drug discovery in India.

Aspire Biopharma regained Nasdaq compliance and avoids delisting after meeting equity requirements.

India's AYUSH federation seeks a national regulator for Yoga and Naturopathy to standardize education and practice.

Jefferies raises Krystal Biotech's price target to $371, citing progress in gene therapy for rare skin diseases.

Fabtech wins ₹63.6 crore contract to build a GMP-compliant pharma plant in West Africa, boosting local medicine production.

AstraZeneca blocked Pharmacor’s generic diabetes drug launch in Australia with a court order, protecting its patent until a full trial.

Doctyn Academy in New Delhi expanded medical training for doctors to boost clinical skills and patient care through hands-on, real-world practice.